Company intelligence / Profile preview

Ting Therapeutics

San Diego, California, United Statestingtherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has characterized a drug called piplartine (TT003) that protects against antibiotics-induced hearing loss in zebrafish and mice as early proof-of-concept data. This work was supported by an NIH SBIR phase I grant which has been extended to a phase II grant to develop TT003.[3]

Therapeutic areas: Neurology
Modalities: Small moleculesrepurposed FDA-approved drugs
Industry: Biotech

Drug pipeline

3 assets

TT-005

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Ting Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ting Therapeutics.

Explore the full profile